Search results for "Intention"

showing 10 items of 453 documents

Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial

2016

International audience; BACKGROUND:We investigated whether sirolimus-based immunosuppression improves outcomes in liver transplantation (LTx) candidates with hepatocellular carcinoma (HCC).METHODS:In a prospective-randomized open-label international trial, 525 LTx recipients with HCC initially receiving mammalian target of rapamycin inhibitor-free immunosuppression were randomized 4 to 6 weeks after transplantation into a group on mammalian target of rapamycin inhibitor-free immunosuppression (group A: 264 patients) or a group incorporating sirolimus (group B: 261). The primary endpoint was recurrence-free survival (RFS); intention-to-treat (ITT) analysis was conducted after 8 years. Overal…

MaleTime FactorsIntention to Treat Analysimedicine.medical_treatmentMedizinPROGRESSIONKaplan-Meier EstimateLiver transplantationGastroenterologyImmunosuppressive Agent0302 clinical medicineEVEROLIMUSRENAL-CELL CARCINOMARisk FactorsMedicine and Health SciencesClinical endpointAge FactorSirolimuProspective StudiesIMMUNOSUPPRESSIONTOR Serine-Threonine KinaseTOR Serine-Threonine KinasesHazard ratioLiver NeoplasmsAge FactorsImmunosuppressionMiddle AgedCANCER3. Good healthIntention to Treat AnalysisEuropeRAPAMYCIN INHIBITORSTreatment OutcomeTARGETLocalLiver Neoplasm030220 oncology & carcinogenesisCombinationDisease ProgressionSURVIVAL[SDV.IMM]Life Sciences [q-bio]/Immunology030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleImmunosuppressive Agentsmedicine.drugHumanAdultmedicine.medical_specialtyCanadaCarcinoma HepatocellularTime Factor[SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/SurgeryRisk AssessmentDisease-Free Survival03 medical and health sciencesYoung AdultDrug TherapyInternal medicinemedicineHumansAdult; Age Factors; Aged; Australia; Canada; Carcinoma Hepatocellular; Disease Progression; Disease-Free Survival; Drug Therapy Combination; Europe; Female; Humans; Immunosuppressive Agents; Intention to Treat Analysis; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence Local; Prospective Studies; Risk Assessment; Risk Factors; Sirolimus; TOR Serine-Threonine Kinases; Time Factors; Treatment Outcome; Young Adult; Liver Transplantation; TransplantationRECURRENCEMETAANALYSISAgedSirolimusTransplantationEverolimusIntention-to-treat analysisbusiness.industryRisk FactorCarcinomaAustraliaHepatocellular3126 Surgery anesthesiology intensive care radiologySurgeryLiver TransplantationTransplantationProspective StudieNeoplasm RecurrenceSirolimusNeoplasm Recurrence Localbusiness
researchProduct

Psychological correlates of physical activity and exercise preferences in metropolitan and nonmetropolitan cancer survivors.

2020

OBJECTIVE: Interventions to increase physical activity (PA) in cancer survivors have often adopted a 'one-size-fits-all' approach, and may benefit from being tailored to psychological constructs associated with behavior. The study objective was to investigate the exercise preferences and psychological constructs related to PA among cancer survivors. METHODS: Post-treatment colorectal, endometrial, and breast cancer survivors (n=183) living in metropolitan and non-metropolitan areas completed survey measures of PA, exercise preferences, attitudes, self-efficacy, perceived behavioral control (PBC), and intention toward PA. RESULTS: A structural equation model with adequate fit and quality ind…

MaleUrban PopulationPsychological interventionPsycho-oncologyExperimental and Cognitive PsychologyIntentionStructural equation modeling03 medical and health sciences0302 clinical medicineBreast cancerCancer SurvivorsSurveys and QuestionnairesPsychological TheorymedicineHumans030212 general & internal medicineExerciseAgedSelf-efficacyAustraliaMiddle Agedmedicine.diseaseSelf EfficacyPsychiatry and Mental healthOncology030220 oncology & carcinogenesisBehavioral medicineExercise intensityFemalePsychologyClinical psychologyPsycho-oncologyREFERENCES
researchProduct

Extended use of dabigatran, warfarin, or placebo in venous thromboembolism

2013

International audience; BACKGROUND: Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be suitable for extended treatment of venous thromboembolism. METHODS: In two double-blind, randomized trials, we compared dabigatran at a dose of 150 mg twice daily with warfarin (active-control study) or with placebo (placebo-control study) in patients with venous thromboembolism who had completed at least 3 initial months of therapy. RESULTS: In the active-control study, recurrent venous thromboembolism occurred in 26 of 1430 patients in the dabigatran group (1.8%) and 18 of 1426 patients in the warfarin group (1.3%) (hazard ratio with dabigatran, 1.44; 95…

Male[SDV]Life Sciences [q-bio]030204 cardiovascular system & hematologyMESH: Intention to Treat AnalysisMESH: Venous Thromboembolism0302 clinical medicineMESH: Aged 80 and overRecurrence030212 general & internal medicineMESH: WarfarinAged 80 and overMESH: AgedMESH: Middle AgedMESH: RiskHazard ratioAtrial fibrillationVenous ThromboembolismGeneral MedicineMESH: Follow-Up StudiesMiddle AgedIntention to Treat Analysis3. Good healthPulmonary embolismMESH: International Normalized RatioMESH: beta-AlanineMESH: Young AdultAnesthesiaFemaleMESH: Hemorrhagemedicine.drugAdultRiskAdolescentHemorrhageLower riskPlaceboDabigatranDabigatran Venous ThromboembolismYoung Adult03 medical and health sciencesmedicineHumansInternational Normalized RatioAgedMESH: AdolescentIntention-to-treat analysisMESH: Humansbusiness.industryWarfarinMESH: Adultmedicine.diseaseMESH: MaleMESH: Recurrencebeta-AlanineBenzimidazolesWarfarinbusinessMESH: BenzimidazolesVenous thromboembolismMESH: FemaleFollow-Up Studies
researchProduct

Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone

2016

BACKGROUND The safe and appropriate use of long-acting beta-agonists (LABAs) for the treatment of asthma has been widely debated. In two large clinical trials, investigators found a potential risk of serious asthma-related events associated with LABAs. This study was designed to evaluate the risk of administering the LABA salmeterol in combination with an inhaled glucocorticoid, fluticasone propionate. METHODS In this multicenter, randomized, double-blind trial, adolescent and adult patients (age, ≥12 years) with persistent asthma were assigned to receive either fluticasone with salmeterol or fluticasone alone for 26 weeks. All the patients had a history of a severe asthma exacerbation in t…

Maleasthma ; serious events ; fluticasone ; salmeterol ; AUSTRIExacerbationIntention to Treat AnalysiINHALED CORTICOSTEROIDSSeverity of Illness Indexlaw.invention0302 clinical medicineRandomized controlled triallawimmune system diseasesÚs terapèuticBroncodilatadors030212 general & internal medicineChildFluticasoneRISKACTING BETA-AGONISTS; INHALED CORTICOSTEROIDS; RISK; EXACERBATIONS; METAANALYSIS; MORTALITY; SAFETY; DEATH; FDAMedicine (all)Hazard ratioDEATHGeneral MedicineBronchodilator agentsMiddle AgedFluticasone-Salmeterol Drug CombinationBronchodilator AgentsIntention to Treat AnalysisAnesthesiaSAFETYFemaleSalmeterolFDAmedicine.drugHumanAdultmedicine.medical_specialtyAdolescentSettore MED/10 - Malattie Dell'Apparato RespiratorioFluticasone propionate03 medical and health sciencesDouble-Blind MethodInternal medicineAdministration InhalationmedicineHumansMETAANALYSISAsmaBronchodilator AgentAsthmaAgedProportional Hazards ModelsFluticasone-Salmeterol Drug Combinationbusiness.industryMORTALITYACTING BETA-AGONISTSTherapeutic usemedicine.diseaseAsthmarespiratory tract diseasesEXACERBATIONS030228 respiratory systemFluticasone Propionate Salmeterol Xinafoate Drug CombinationProportional Hazards ModelFluticasonebusiness
researchProduct

Effectiveness of a transdiagnostic internet-based protocol for the treatment of emotional disorders versus treatment as usual in specialized care: st…

2015

Emotional disorders (depression and anxiety disorders) are highly prevalent mental health problems. Although evidence showing the effectiveness of disorder-specific treatments exists, high comorbidity rates among emotional disorders limit the utility of these protocols. This has led some researchers to focus their interest on transdiagnostic interventions, a treatment perspective that might be more widely effective across these disorders. Also, the current way of delivering treatments makes it difficult provide assistance to all of the population in need. The use of the Internet in the delivery of evidence-based treatments may help to disseminate treatments among the population. In this stu…

Malemedicine.medical_specialtyGeneralized anxiety disorderTime FactorsEmotionsPsychological interventionMedicine (miscellaneous)AnxietyStudy ProtocolClinical ProtocolsSurveys and QuestionnairesmedicineHumansPharmacology (medical)PsychiatryComputer-delivered psychotherapyPsychiatric Status Rating ScalesTransdiagnosticExtraversion/behavioral activationDepressive DisorderInternetbusiness.industryDepressionPanic disorderSocial anxietyEmotional disordersmedicine.diseaseNeuroticism/behavioral inhibitionNeuroticismAnxiety DisordersIntention to Treat AnalysisPsychotherapyTreatment OutcomePatient SatisfactionResearch DesignSpainRandomized controlled trialTherapy Computer-AssistedQuality of LifeAnxietyFemalemedicine.symptombusinessDelivery of Health CareAnxiety disorderAgoraphobiaClinical psychologyTrials
researchProduct

Effect of a 2-year diet intervention with walnuts on cognitive decline. The Walnuts And Healthy Aging (WAHA) study: a randomized controlled trial

2019

Background Walnut consumption counteracts oxidative stress and inflammation, 2 drivers of cognitive decline. Clinical data concerning effects on cognition are lacking. Objectives The Walnuts And Healthy Aging study is a 2-center (Barcelona, Spain; Loma Linda, CA) randomized controlled trial examining the cognitive effects of a 2-y walnut intervention in cognitively healthy elders. Methods We randomly allocated 708 free-living elders (63-79 y, 68% women) to a diet enriched with walnuts at ∼15% energy (30-60 g/d) or a control diet (abstention from walnuts). We administered a comprehensive neurocognitive test battery at baseline and 2 y. Change in the global cognition composite was the primary…

Malemedicine.medical_specialtyMedicine (miscellaneous)Juglanslaw.inventionHealthy Aging03 medical and health sciences0302 clinical medicineRandomized controlled trialMemorylawInternal medicineIntervention (counseling)medicineHumansNutsCognitive Dysfunction030212 general & internal medicineCognitive declineAgedNutrition and DieteticsIntention-to-treat analysismedicine.diagnostic_testbusiness.industryBrainCognitionNeuropsychological testMiddle AgedMagnetic Resonance ImagingSpainCohortFemalebusinessNeurocognitive030217 neurology & neurosurgeryThe American Journal of Clinical Nutrition
researchProduct

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

2015

BACKGROUND: Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol levels in patients who are receiving statin therapy. Larger and longer-term studies are needed to establish safety and efficacy.METHODS: We conducted a randomized trial involving 2341 patients at high risk for cardiovascular events who had LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or more and were receiving treatment with statins at the maximum tolerated dose (the highest dose associated with an acceptable side-effect profile), with or without other lipid-lowering therapy. Patients were …

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaIntention to Treat AnalysiHypercholesterolemiaUrologyalirocumabBococizumabPharmacologyPlaceboAged; Antibodies Monoclonal; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol LDL; Double-Blind Method; Drug Therapy Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intention to Treat Analysis; Male; Middle Aged; Medicine (all)law.inventionchemistry.chemical_compoundcardiovascular eventsDouble-Blind MethodRandomized controlled triallawCardiovascular DiseaseAnticholesteremic AgentMedicineproprotein convertase subtilisin–kexin type 9 (PCSK9)High Cardiovascular Risk PatientsAgedAlirocumabalirocumab; cholesterol; cardiovascular eventsCholesterolbusiness.industryMedicine (all)PCSK9Antibodies MonoclonalcholesterolCholesterol LDLGeneral MedicineMiddle AgedLomitapideEvolocumabchemistrylow-density lipoprotein (LDL) cholesterol[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieDrug Therapy CombinationFemalelipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitorbusiness[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyHumanNew England journal of medicine
researchProduct

Intention-to-treat survival benefit of liver transplantation in patients with hepatocellular cancer

2017

The debate about the best approach to select patients with hepatocellular cancer (HCC) waiting for liver transplantation (LT) is still ongoing. This study aims to identify the best variables allowing to discriminate between "high-" and "low-benefit" patients. To do so, the concept of intention-to-treat (ITT) survival benefit of LT has been created. Data of 2,103 adult HCC patients consecutively enlisted during the period 1987-2015 were analyzed. Three rigorous statistical steps were used in order to create the ITT survival benefit of LT: the development of an ITT LT and a non-LT survival model, and the individual prediction of the ITT survival benefit of LT defined as the difference between…

Malemedicine.medical_specialtySettore MED/18 - CHIRURGIA GENERALEmedicine.medical_treatment030230 surgeryMilan criteriaLiver transplantation03 medical and health sciencesLiver disease0302 clinical medicineInternal medicinemedicineCarcinoma Hepatocellular; Europe; Female; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Liver Transplantation; HepatologyHumansRisk factorHepatology; hepatocellular cancer; liver transplantationCarcinoma Hepatocellular; Europe; Female; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Liver TransplantationSurvival analysisRetrospective StudiesIntention-to-treat analysisHepatologybusiness.industryCarcinomaLiver NeoplasmsRetrospective cohort studyHepatocellularHepatologyMiddle Agedmedicine.diseaseSurgeryLiver TransplantationSettore MED/18Europehepatocellular cancer030211 gastroenterology & hepatologyFemalebusiness
researchProduct

Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inf…

2015

AbstractZostavax® is a live, attenuated varicella zoster virus (VZV) vaccine developed specifically for the prevention of HZ and PHN in individuals aged ≥50 years. During the clinical development of Zostavax, which was mainly in the US, the vaccine was administrated by the subcutaneous (SC) route. In Europe, many healthcare professionals prefer administering vaccines by the intramuscular (IM) route. This was an open-label, randomised trial conducted in 354 subjects aged ≥50 years. The primary objectives were to demonstrate that IM administration is both non-inferior to SC administration in terms of 4-week post-vaccination geometric mean titres (GMTs), and elicits an acceptable geometric mea…

Malemedicine.medical_specialtySub-cutaneous administration routeEnzyme-Linked Immunospot AssayHerpesvirus 3 HumanInjections SubcutaneousVaricella zoster virus vaccinePainmedicine.disease_causeAntibodies ViralVaccines AttenuatedHerpes ZosterInjections Intramuscularlaw.inventionShinglesInterferon-gammaRandomized controlled triallawImmunology and Microbiology(all)Internal medicinemedicineEdemaHerpes Zoster VaccineHumansAdverse effectAgedRandomised controlled trialAged 80 and overAttenuated vaccineIntention-to-treat analysisGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryELISPOTImmunogenicityVaccinationPublic Health Environmental and Occupational HealthVaricella zoster virusIntramuscular administration routeMiddle Agedmedicine.diseaseveterinary(all)Infectious DiseasesErythemaImmunologyMolecular MedicineFemalebusinessShinglesVaccine
researchProduct

Keeping memory for intentions: A cTBS investigation of the frontopolar cortex

2011

The present study aimed to investigate the role of frontopolar cortex in prospective memory (PM) by means of inhibitory theta-burst stimulation (cTBS). "Experiment 1"-8 volunteers were evaluated after inhibitory cTBS over left Brodmann area (BA) 10, right BA10, and Cz. In the PM procedure, sequences of 4 words each were presented. During the intersequence delay, subjects had to repeat the sequence in the observed order (ongoing task forward) or in the reverse order (backward). At the occurrence of a target word, subjects had to press a key on the keyboard (PM task). Recall and recognition of the target words were also tested. PM accuracy was lower after cTBS over left BA10 compared with Cz …

Malemedicine.medical_specialtymedicine.medical_treatmentCognitive NeuroscienceCTBStmprospective rememberingPrefrontal CortexBrodmann area 10IntentionAudiologyCognitive neuroscienceNOYoung AdultCellular and Molecular NeuroscienceMemoryProspective memorymedicineReaction TimeHumansdelayed intentionsTheta RhythmPrefrontal cortexRecallfrontal cortexYoung Adult; Theta Rhythm; Memory; Humans; Intention; Prefrontal Cortex; Transcranial Magnetic Stimulation; Male; Female; Reaction TimeTranscranial Magnetic StimulationTranscranial magnetic stimulationprefrontal regionsBrodmann area 10Brodmann area 10; delayed intentions; prefrontal regions; prospective remembering; transcranial magnetic stimulationprefrontal regionSettore MED/26 - Neurologiadelayed intentionFemalePsychologyNeuroscienceBrodmann areaHuman
researchProduct